Rania Bassiouni
Overview
Explore the profile of Rania Bassiouni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang M, Shen H, Flodby P, Koss M, Bassiouni R, Liu Y, et al.
Cell Rep
. 2023 Nov;
42(12):113286.
PMID: 37995179
Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer and presents clinically with a high degree of biological heterogeneity and distinct clinical outcomes. The current paradigm of LUAD...
2.
Bassiouni R, Idowu M, Gibbs L, Robila V, Grizzard P, Webb M, et al.
Cancer Res
. 2022 Oct;
83(1):34-48.
PMID: 36283023
Significance: Spatial transcriptomics profiling of a diverse cohort of triple-negative breast cancers and innovative informatics approaches reveal a conserved cellular architecture across cancers and identify proportional differences in tumor cell...
3.
Baldelli E, El Gazzah E, Moran J, Hodge K, Manojlovic Z, Bassiouni R, et al.
Genes (Basel)
. 2021 Sep;
12(9).
PMID: 34573384
mutations are one of the most common oncogenic drivers in non-small cell lung cancer (NSCLC) and in lung adenocarcinomas in particular. Development of therapeutics targeting KRAS has been incredibly challenging,...
4.
Bassiouni R, Gibbs L, Craig D, Carpten J, McEachron T
Mol Cell
. 2021 Apr;
81(8):1631-1639.
PMID: 33826920
Spatial transcriptional profiling provides gene expression information within the important anatomical context of tissue architecture. This approach is well suited to characterizing solid tumors, which develop within a complex landscape...
5.
Carr A, Khaled A, Bassiouni R, Flores O, Nierenberg D, Bhatti H, et al.
Oncotarget
. 2018 Jan;
8(66):110273-110288.
PMID: 29299146
Identifying new druggable targets is desired to meet the needs for effective cancer treatments. To this end, we previously reported the efficacy of a therapeutic peptide called CT20p that displays...
6.
Flores O, Santra S, Kaittanis C, Bassiouni R, Khaled A, Khaled A, et al.
Theranostics
. 2017 Jul;
7(9):2477-2494.
PMID: 28744329
Herein, we report the use of a theranostic nanocarrier (Folate-HBPE(CT20p)) to deliver a therapeutic peptide to prostate cancer tumors that express PSMA (folate hydrolase 1). The therapeutic peptide (CT20p) targets...
7.
Bassiouni R, Nemec K, Iketani A, Flores O, Showalter A, Khaled A, et al.
Clin Cancer Res
. 2016 Mar;
22(17):4366-79.
PMID: 27012814
Purpose: Metastatic disease is a leading cause of death for patients with breast cancer, driving the need for new therapies. CT20p is a peptide previously discovered by our group that...
8.
Andrade C, Yanez C, Qaddoura M, Wang X, Arnett C, Coombs S, et al.
J Fluoresc
. 2011 Jan;
21(3):1223-30.
PMID: 21243414
We report two-photon fluorescence microscopy (2PFM) imaging and in vitro cell viability of a new, efficient, lysosome-selective system based on a two-photon absorbing (2PA) fluorescent probe (I) encapsulated in Pluronic®...